Skip to main content
Erschienen in: Tumor Biology 4/2015

01.04.2015 | Research Article

miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1

verfasst von: Ye Zhang, Xiujuan Qu, Ce Li, Yibo Fan, Xiaofang Che, Ximing Wang, Ying Cai, Xuejun Hu, Yunpeng Liu

Erschienen in: Tumor Biology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs (miRNAs) are a class of non-protein-coding small RNAs with the capacity to regulate fundamental biological processes essential for cancer initiation and progression. In the present study, we analyzed miRNA expression levels between multidrug-resistant gastric carcinoma cell line SGC7901/ADR and its parent cell line SGC7901 using a miRNA microarray. MiR-103/107 was downregulated compared with parental SGC7901 cells. Overexpression of miR-103/107 sensitized SGC7901/ADR cells to doxorubicin (DOX), as demonstrated by in vitro and in vivo drug sensitivity assay. We further confirmed that miR-103/107 inhibited P-gp function in gastric cancer SGC7901/ADR cells. Finally, we verified that caveolin-1 (Cav-1), a critical component of lipid rafts, was a target of miR-103/107.
Literatur
1.
Zurück zum Zitat Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39:60–7.CrossRefPubMed Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013;39:60–7.CrossRefPubMed
2.
Zurück zum Zitat Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discov Today. 2011;16:755–61.PubMedPubMedCentral Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discov Today. 2011;16:755–61.PubMedPubMedCentral
3.
Zurück zum Zitat Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013;19:7126–40.CrossRefPubMed Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013;19:7126–40.CrossRefPubMed
4.
Zurück zum Zitat Papp E, Gadawski I, Côté HC. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother. 2008;61:1048–52.CrossRefPubMed Papp E, Gadawski I, Côté HC. Longitudinal effects of thymidine analogues on mtDNA, mtRNA and multidrug resistance (MDR-1) induction in cultured cells. J Antimicrob Chemother. 2008;61:1048–52.CrossRefPubMed
5.
Zurück zum Zitat Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008;7:670–8.CrossRefPubMed Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 2008;7:670–8.CrossRefPubMed
6.
Zurück zum Zitat Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162:1096–108.CrossRefPubMedPubMedCentral Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162:1096–108.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Guo Q, Nan XX, Yang JR, Yi L, Liang BL, Wei YB, et al. Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Neoplasma. 2013;60:598–604.CrossRefPubMed Guo Q, Nan XX, Yang JR, Yi L, Liang BL, Wei YB, et al. Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Neoplasma. 2013;60:598–604.CrossRefPubMed
8.
Zurück zum Zitat Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51.CrossRefPubMedPubMedCentral Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis. 2013;2:e51.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets. 2012;12:716–40.CrossRefPubMed Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets. 2012;12:716–40.CrossRefPubMed
10.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
11.
Zurück zum Zitat Krützfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet. 2006;38:S14–9.CrossRefPubMed Krützfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function of microRNAs. Nat Genet. 2006;38:S14–9.CrossRefPubMed
12.
Zurück zum Zitat Hong L, Yang Z, Ma J, Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013;14:1118–27.CrossRefPubMed Hong L, Yang Z, Ma J, Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 2013;14:1118–27.CrossRefPubMed
13.
Zurück zum Zitat Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012;29:2527–34.CrossRefPubMed Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 2012;29:2527–34.CrossRefPubMed
14.
Zurück zum Zitat Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 2013;52:70–8.CrossRefPubMed Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 2013;52:70–8.CrossRefPubMed
15.
Zurück zum Zitat Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 2012;44:269–77.CrossRef Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai). 2012;44:269–77.CrossRef
16.
Zurück zum Zitat Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47:346–56.CrossRefPubMed Zhang S, Wan Y, Pan T, Gu X, Qian C, Sun G, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. J Mol Neurosci. 2012;47:346–56.CrossRefPubMed
17.
Zurück zum Zitat Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2:720–7.CrossRefPubMedPubMedCentral Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2:720–7.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.CrossRefPubMed Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012;29:384–91.CrossRefPubMed
19.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
20.
Zurück zum Zitat Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang J, et al. β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183.CrossRefPubMedPubMedCentral Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang J, et al. β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, et al. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol. 2009;218:248–55.CrossRefPubMed Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, et al. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol. 2009;218:248–55.CrossRefPubMed
22.
Zurück zum Zitat Zhang Y, Mu X, Li E, Luo Y, Song N, Qu X, et al. The role of E3 ubiquitin ligase Cbl proteins in β-Elemene reversing multi-drug resistance of human leukemia and gastric cancer cells. Int J Mol Sci. 2013;14:10075–89.CrossRefPubMedPubMedCentral Zhang Y, Mu X, Li E, Luo Y, Song N, Qu X, et al. The role of E3 ubiquitin ligase Cbl proteins in β-Elemene reversing multi-drug resistance of human leukemia and gastric cancer cells. Int J Mol Sci. 2013;14:10075–89.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–53.CrossRefPubMed Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–53.CrossRefPubMed
24.
Zurück zum Zitat Yun UJ, Lee JH, Koo KH, Ye SK, Kim SY, Lee CH, et al. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem Pharmacol. 2013;85:1441–53.CrossRefPubMed Yun UJ, Lee JH, Koo KH, Ye SK, Kim SY, Lee CH, et al. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem Pharmacol. 2013;85:1441–53.CrossRefPubMed
25.
Zurück zum Zitat Orlowski S, Martin S, Escargueil A. P-glycoprotein and ‘lipid rafts’: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci. 2006;63:1038–59.CrossRefPubMed Orlowski S, Martin S, Escargueil A. P-glycoprotein and ‘lipid rafts’: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?). Cell Mol Life Sci. 2006;63:1038–59.CrossRefPubMed
26.
Zurück zum Zitat Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matkó J, et al. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A. 2004;61:105–16.CrossRefPubMed Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matkó J, et al. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A. 2004;61:105–16.CrossRefPubMed
27.
Zurück zum Zitat Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. J Lipid Res. 2004;45:1910–8.CrossRefPubMed Modok S, Heyward C, Callaghan R. P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment. J Lipid Res. 2004;45:1910–8.CrossRefPubMed
28.
Zurück zum Zitat Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012;15:98–105.CrossRefPubMedPubMedCentral Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012;15:98–105.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–46.CrossRefPubMed Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–46.CrossRefPubMed
30.
Zurück zum Zitat Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol. 2010;31:643–50.CrossRefPubMed Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, et al. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol. 2010;31:643–50.CrossRefPubMed
31.
Zurück zum Zitat Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One. 2013;8:e61524.CrossRefPubMedPubMedCentral Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One. 2013;8:e61524.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59:105–10.CrossRefPubMed Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59:105–10.CrossRefPubMed
Metadaten
Titel
miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1
verfasst von
Ye Zhang
Xiujuan Qu
Ce Li
Yibo Fan
Xiaofang Che
Ximing Wang
Ying Cai
Xuejun Hu
Yunpeng Liu
Publikationsdatum
01.04.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2835-7

Weitere Artikel der Ausgabe 4/2015

Tumor Biology 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.